In last trading session, Ascendis Pharma A/S (NASDAQ:ASND) saw 178,962 shares changing hands with its beta currently measuring 0.72. Company’s recent per share price level of $121.95 trading at -$2.23 or -1.8% at ring of the bell on the day assigns it a market valuation of $6.56 Billion. That closing price of ASND’s stock is at a discount of -50.87% from its 52-week high price of $183.98 and is indicating a premium of 3.68% from its 52-week low price of $117.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 203.62 Million shares which gives us an average trading volume of 209.45 Million if we extend that period to 3-months.
For Ascendis Pharma A/S (ASND), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.6. Splitting up the data highlights that, out of 14 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 13 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$2.06 in the current quarter.
Ascendis Pharma A/S (NASDAQ:ASND) trade information
In the face of being in the red during last session for losing -1.8%, in the last five days ASND remained trading in the green while hitting it’s week-highest on Wednesday, Apr 14 when the stock touched $128 price level, adding 4.73% to its value on the day. Ascendis Pharma A/S’s shares saw a change of -26.88% in year-to-date performance and have moved -2.91% in past 5-day. Ascendis Pharma A/S (NASDAQ:ASND) showed a performance of -17.04% in past 30-days. Number of shares sold short was 2.93 Million shares which calculate 0.01 days to cover the short interests.
Ascendis Pharma A/S (ASND) estimates and forecasts
Statistics highlight that Ascendis Pharma A/S is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -22.69% of value to its shares in past 6 months, showing an annual growth rate of -5.71% while that of industry is 7.8. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -36.4% in the current quarter and calculating 0.4% increase in the next quarter. This year revenue growth is estimated to rise 307.7% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.25 Million for the same. And 7 analysts are in estimates of company making revenue of $2.25 Million in the next quarter that will end on June 01, 2021. Company posted $2.11 Million and $1.7 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 6.6% while estimating it to be 32.7% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -76.6% while estimates for its earnings growth in next 5 years are of 24%
Ascendis Pharma A/S (NASDAQ:ASND)’s Major holders
Insiders are in possession of 0.03% of company’s total shares while institution are holding 102.82% percent of that, with stock having share float percentage of 102.85%. Investors also watch the number of corporate investors in a company very closely, which is 246 institutions for Ascendis Pharma A/S that are currently holding shares of the company. Price (T.Rowe) Associates Inc is the top institutional holder at ASND for having 6.62 Million shares of worth $1.1 Billion. And as of December 30, 2020, it was holding 12.31% of the company’s outstanding shares.
The second largest institutional holder is RA Capital Management, L.P., which was holding about 5.87 Million shares on December 30, 2020. The number of shares represents firm’s hold over 10.91% of outstanding shares, having a total worth of $978.22 Million.
On the other hand, Price (T.Rowe) New Horizons Fund and Mutual Fund Ser Tr-Eventide Gilead Fund are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 1157009 shares of worth $192.97 Million or 2.15% of the total outstanding shares. The later fund manager was in possession of 1.12 Million shares on December 30, 2020, making its stake of worth around $187.29 Million in the company or a holder of 2.09% of company’s stock.